Department of Microbiology & Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
J Infect Dis. 2011 Aug 15;204(4):582-91. doi: 10.1093/infdis/jir094. Epub 2011 Jun 17.
A major goal in influenza vaccine development is induction of serological memory and cellular responses to confer long-term protection and limit virus spread after infection. Here, we investigate induction of long-lived immunity against the 2009 H1N1 virus after skin vaccination.
BALB/c mice received a single dose of 5 μg inactivated A/California/04/09 virus via coated metal microneedles (MN) applied to skin or via subcutaneous injection.
MN or subcutaneous vaccination elicited similar serum IgG and hemagglutination inhibition titers and 100% protection against lethal viral challenge 6 weeks after vaccination. Six months after vaccination, the subcutaneous group exhibited a 60% decrease in functional antibody titers and extensive lung inflammation after challenge with 10 × LD(50) of homologous virus. In contrast, the MN group maintained high functional antibody titers and IFN-γ levels, inhibition of viral replication, and no signs of lung inflammation after challenge. MN vaccination conferred complete protection against lethal challenge, whereas subcutaneous vaccination induced only partial protection. These findings were further supported by high numbers of bone marrow plasma cells and spleen antibody-secreting cells detected in the MN group.
A single skin vaccination with MN induced potent long-lived immunity and improved protection against the 2009 H1N1 influenza virus, compared with subcutaneous injection.
流感疫苗开发的主要目标是诱导血清记忆和细胞应答,以提供长期保护并限制感染后的病毒传播。在这里,我们研究了经皮接种诱导对 2009 年 H1N1 病毒产生长期免疫的情况。
BALB/c 小鼠通过涂覆金属微针(MN)或皮下注射,单次给予 5μg 灭活的 A/California/04/09 病毒。
MN 或皮下接种均可诱导相似的血清 IgG 和血凝抑制滴度,并在接种后 6 周对致死性病毒攻击提供 100%的保护。接种 6 个月后,皮下组在接受同源病毒 10×LD50 挑战后,功能性抗体滴度下降 60%,肺部炎症广泛。相比之下,MN 组在挑战后保持高功能性抗体滴度和 IFN-γ 水平,抑制病毒复制,且无肺部炎症迹象。MN 接种可完全预防致死性挑战,而皮下接种仅诱导部分保护。这些发现进一步得到了 MN 组骨髓浆细胞和脾抗体分泌细胞数量高的支持。
与皮下注射相比,单次经皮 MN 接种可诱导强烈的长期免疫,并改善对 2009 年 H1N1 流感病毒的保护。